fondaparinux has been researched along with Peripheral-Arterial-Disease* in 1 studies
1 other study(ies) available for fondaparinux and Peripheral-Arterial-Disease
| Article | Year |
|---|---|
Clinical safety of low-dose anticoagulation with fondaparinux in patients undergoing peripheral endovascular treatment due to critical limb-threatening ischaemia - a pilot study.
To evaluate the safety and effectiveness of fondaparinux in addition to dual antiplatelet therapy (DAPT) in patients with critical limb-threatening ischaemia (CLTI).. Fondaparinux (2.5 mg/d) was administered for 1-4 weeks after endovascular procedures together with DAPT (. Adding fondaparinux to DAPT does not seem to result in excess of clinically relevant bleeding. Our preliminary data suggest that prospective studies are now warranted in larger patient cohorts.. DRKS00015856. Topics: Anticoagulants; Endovascular Procedures; Female; Femoral Artery; Fondaparinux; Humans; Ischemia; Limb Salvage; Peripheral Arterial Disease; Pilot Projects; Platelet Aggregation Inhibitors; Popliteal Artery; Prospective Studies; Retrospective Studies; Stents; Treatment Outcome; Vascular Patency | 2021 |